Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Irinotecan + Pyrotinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Irinotecan | Camptosar | CPT-11|Onivyde | TOPO1 inhibitor 10 | Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
Pyrotinib | SHR-1258|SHR1258 | EGFR Inhibitor (Pan) 58 HER2 Inhibitor 40 | Pyrotinib is an irreversible dual inhibitor of EGFR and ERBB2 (HER2), which potentially leads to decreased growth of EGFR and/or HER2-positive tumor cells (PMID: 28115222, PMID: 30596880). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ERBB3 V104L | gastric adenocarcinoma | predicted - sensitive | Irinotecan + Pyrotinib | Case Reports/Case Series | Actionable | In a clinical case study, combination treatment Camptosar (irinotecan) and Pyrotinib in a patient with metastatic gastric adenocarcinoma harboring ERBB3 V104L, who had relapsed on prior treatment with chemotherapy, led to stable disease and a progression-free survival of 7.6 months (PMID: 33500629). | 33500629 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|